Table 3 Demographic characteristics of the two groups with distinct prognostic features
Variables | Overall (n = 94) | Low-risk group (n = 60) | High-risk group (n = 34) | P value |
|---|---|---|---|---|
Age, years | 78.70 ± 7.76 | 76.0 ± 7.60 | 83.5 ± 5.47 | <0.001 |
T stage | 0.028 | |||
T0-T1 | 13 (13.8%) | 12 (20.0%) | 1 (2.94%) | |
T2-T4 | 81 (86.2%) | 48 (80.0%) | 33 (97.1%) | |
N stage | 0.589 | |||
N0, Nx | 76 (80.9%) | 50 (83.3%) | 26 (76.5%) | |
N1 | 18 (19.1%) | 10 (16.7%) | 8 (23.5%) | |
M stage | 1.000 | |||
M0, Mx | 64 (68.1%) | 41 (68.3%) | 23 (67.6%) | |
M1 | 30 (31.9%) | 19 (31.7%) | 11 (32.4%) | |
Treatment protocols | 0.454 | |||
ADT | 69 (73.4%) | 42 (70.0%) | 27 (79.4%) | |
Others | 25 (26.6%) | 18 (30.0%) | 7 (20.6%) | |
Prostate-specific antigen, ng/mL | 75.3 ± 57.7 | 75.6 ± 56.7 | 74.7 ± 60.3 | 0.945 |
Total CD3(+)T lymphocytes, cells/µL | 0.159 | |||
< 1203.05 | 71 (75.5%) | 42 (70.0%) | 29 (85.3%) | |
≥ 1203.05 | 23 (24.5%) | 18 (30.0%) | 5 (14.7%) | |
CD3(+) CD4(+)T lymphocytes, cells/µL | <0.001 | |||
< 365.10 | 16 (17.0%) | 3 (5.00%) | 13 (38.2%) | |
≥ 365.10 | 78 (83.0%) | 57 (95.0%) | 21 (61.8%) | |
CD3(+) CD8(+)T lymphocytes, cells/µL | 0.963 | |||
< 443.45 | 68 (72.3%) | 44 (73.3%) | 24 (70.6%) | |
≥ 443.45 | 26 (27.7%) | 16 (26.7%) | 10 (29.4%) | |
CD4(+)/CD8(+) ratio | <0.001 | |||
< 1.10 | 17 (18.1%) | 4 (6.67%) | 13 (38.2%) | |
≥ 1.10 | 77 (81.9%) | 56 (93.3%) | 21 (61.8%) | |
Total CD19(+)B lymphocytes, cells/µL | <0.001 | |||
< 45.83 | 15 (16.0%) | 2 (3.33%) | 13 (38.2%) | |
≥ 45.83 | 79 (84.0%) | 58 (96.7%) | 21 (61.8%) | |
CD19(+) CD5(+)B lymphocytes, cells/µL | <0.001 | |||
< 5.76 | 10 (10.6%) | 1 (1.67%) | 9 (26.5%) | |
≥ 5.76 | 84 (89.4%) | 59 (98.3%) | 25 (73.5%) | |
CD19(+) CD5(-)B lymphocytes, cells/µL | <0.001 | |||
< 35.65 | 15 (16.0%) | 2 (3.33%) | 13 (38.2%) | |
≥ 35.65 | 79 (84.0%) | 58 (96.7%) | 21 (61.8%) | |
CD3(-)CD16(+)CD56(+)NK cells, cells/µL | 0.015 | |||
< 238.87 | 36 (38.3%) | 29 (48.3%) | 7 (20.6%) | |
≥ 238.87 | 58 (61.7%) | 31 (51.7%) | 27 (79.4%) |